Processa pharmaceuticals ceo dr. david young issues letter to shareholders providing outlook for 2022

Hanover, md., jan. 26, 2022 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, today released the following letter to shareholders from its chief executive officer dr. david young.
PCSA Ratings Summary
PCSA Quant Ranking